As of 2024-07-27, the EV/EBITDA ratio of Lexicon Pharmaceuticals Inc (LXRX) is -4.91. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. LXRX's latest enterprise value is 867.22 mil USD. LXRX's TTM EBITDA according to its financial statements is -176.69 mil USD. Dividing these 2 quantities gives us the above LXRX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.5x - 22.9x | 16.6x |
| Forward P/E multiples | 16.6x - 24.5x | 21.4x |
| Fair Price | (8.12) - (11.20) | (9.30) |
| Upside | -439.9% - -568.8% | -489.0% |
| Date | EV/EBITDA |
| 2024-07-26 | -4.91 |
| 2024-07-25 | -4.79 |
| 2024-07-24 | -4.46 |
| 2024-07-23 | -4.56 |
| 2024-07-22 | -4.34 |
| 2024-07-19 | -4.09 |
| 2024-07-18 | -4.29 |
| 2024-07-17 | -4.38 |
| 2024-07-16 | -4.58 |
| 2024-07-15 | -4.36 |
| 2024-07-12 | -4.07 |
| 2024-07-11 | -3.82 |
| 2024-07-10 | -3.35 |
| 2024-07-09 | -3.29 |
| 2024-07-08 | -3.29 |
| 2024-07-05 | -3.44 |
| 2024-07-03 | -3.41 |
| 2024-07-02 | -3.29 |
| 2024-07-01 | -3.45 |
| 2024-06-28 | -3.46 |
| 2024-06-27 | -3.58 |
| 2024-06-26 | -3.46 |
| 2024-06-25 | -3.50 |
| 2024-06-24 | -3.72 |
| 2024-06-21 | -3.80 |
| 2024-06-20 | -3.60 |
| 2024-06-18 | -3.60 |
| 2024-06-17 | -3.54 |
| 2024-06-14 | -3.74 |
| 2024-06-13 | -3.76 |
| 2024-06-12 | -3.93 |
| 2024-06-11 | -3.97 |
| 2024-06-10 | -3.91 |
| 2024-06-07 | -3.60 |
| 2024-06-06 | -3.60 |
| 2024-06-05 | -3.99 |
| 2024-06-04 | -3.62 |
| 2024-06-03 | -3.60 |
| 2024-05-31 | -3.50 |
| 2024-05-30 | -3.50 |
| 2024-05-29 | -3.37 |
| 2024-05-28 | -3.48 |
| 2024-05-24 | -3.33 |
| 2024-05-23 | -3.31 |
| 2024-05-22 | -3.44 |
| 2024-05-21 | -3.44 |
| 2024-05-20 | -3.64 |
| 2024-05-17 | -3.64 |
| 2024-05-16 | -3.78 |
| 2024-05-15 | -3.99 |